

Rhythm Biosciences establishes strategic partnership with AGRF to accelerate commercial scale-up of the Genetype service

Highlights

- ✓ Rhythm has partnered with Australia's leading genomics research institute to establish Australian-based, commercial-scale processing capability for geneType™ clinical services, enabling capacity to process > 100,000 tests annually to support local customer demand.
- ✓ The addition of an Australian reference lab will reduce regional turnaround time, improve clinician responsiveness, and allow Australian patient samples to be processed and retained within the country.
- ✓ The partnership positions Rhythm to support its planned H2 2026 expansion into additional markets, leveraging AGRF as a scalable regional processing hub.
- ✓ Operational redundancy with dual laboratory partners (AGRF and Gene by Gene) reduces supply chain risk and supports service continuity as demand scales.

Melbourne, Australia, 29th January 2026: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company announces a new partnership with the Australian Genome Research Facility (AGRF Ltd), establishing AGRF as an Australian-based reference laboratory for geneType™ genotyping services to support commercial deployment and long-term scale-up. This strategic expansion complements Rhythm's existing partnership with Gene by Gene in the United States and strengthens the Company's global laboratory network capable of supporting commercial-scale deployment.

Under the agreement, AGRF will conduct geneType™ genotyping domestically utilising Rhythm's proprietary custom Illumina-based Infinium array, enabling Australian samples to be processed within the country. This delivers multiple commercial advantages: a reduction in turnaround times due to streamlined logistics, reduction of per-test shipping costs, improved service responsiveness for healthcare providers, and enhanced service continuity for clinicians and patients while maintaining the highest standards of analytical quality. The dual-laboratory model provides a resilient and scalable operating model critical for scaling commercial operations. Importantly, processing biospecimens

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Gavin Fox-Smith	Non-Executive Chairman
Sue MacLeman	Non-Executive Director
David Atkins	CEO & Managing Director

within Australia provides additional assurance that patient privacy and data security are protected under Australian regulations, a key differentiator for privacy-conscious healthcare providers and patients.

AGRF is Australia's leading national genomics service provider with over 25 years of experience, processing more than 500,000 samples annually across advanced sequencing, genotyping, and accredited laboratory operations (ISO 15189, NATA). Their capabilities and infrastructure align with Rhythm's mission to deliver reliable and scalable precision health solutions to the Australian market. AGRF's established clinical-grade infrastructure eliminates the need for significant capital investment by Rhythm, supporting capital-efficient growth, while ensuring world-class quality standards.

Rhythm's proprietary analysis pipeline is capable of regional deployment and facilitates engagement with local laboratory partners, supporting compliance with applicable data privacy and data sovereignty laws. With a scalable capacity across both laboratory partners, Rhythm is now well-positioned to meet growing demand as commercial adoption accelerates through healthcare provider partnerships and consumer-initiated channels. The Australian processing capability particularly strengthens Rhythm's ability to compete for institutional contracts where data sovereignty and rapid turnaround times, and local processing capability are key selection criteria.

Rhythm will work closely with AGRF to complete onboarding and validation activities, with Australian-based processing expected to commence in Q3 FY26. Furthermore, this new capability directly supports Rhythm's expansion into Southeast Asia planned for H2 2026. The regional hub model leveraging Australian infrastructure provides a capital-efficient, scalable foundation for international growth while maintaining consistent quality standards.

Dr David Atkins, Rhythm CEO & MD commented "*We're delighted to be working with a partner of AGRF's calibre to deliver world-class cancer risk assessment services through an all-Australian supply chain. This partnership represents a significant step in our commercialisation strategy, strengthening our operating model to support sustainable revenue growth, providing the operational capacity and geographic reach needed to scale our geneType™ platform across Australia and into Southeast Asian*

markets. The dual-laboratory model with AGRF and Gene by Gene ensures we can reliably serve growing demand while maintaining the highest quality standards and protecting patient data under Australian regulations. For our shareholders, this partnership translates to reduced operational risk, improved unit economics, and enhanced scalability of our geneType™ platform through faster turnaround and lower logistics costs, and a stronger competitive position in both domestic and international markets. This agreement supports our objective of building a globally scalable, capital efficient diagnostics business."

Desley Pitcher, AGRF Head of Strategic Business commented "AGRF is proud to partner with Rhythm Biosciences to help bring advanced genetic risk assessment services to Australian clinicians and patients. With more than 25 years of experience delivering high-quality genomic services across our national laboratory network, AGRF offers deep local expertise and the clinical-grade rigour expected of a NATA-accredited (ISO15189) provider. This partnership with Rhythm Biosciences ensures that Australian samples are processed here in Australia with the highest levels of analytical quality, data security, and operational reliability. It reflects our ongoing commitment to translating leading genomic innovations into accessible, nationally delivered services that improve health outcomes. We look forward to supporting Rhythm as it expands across Australia and the broader Asia–Pacific region."

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with like-minded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalised health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease



assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genotype.com.

About AGRF

AGRF, Ltd is Australia's leading provider of multi-omic services and expertise. With laboratories across the country, AGRF empowers researchers, clinicians and industry partners to deliver genomic data in health, agriculture and the environment. Our expertise spans sequencing, genotyping, transcriptomics, epigenomics, proteomics, and bioinformatics, enabling discovery and translation at scale. Trusted for quality and collaboration, AGRF supports national and international projects that drive innovation, improve lives, and shape the future.